These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11387906)

  • 1. Escherichia coli infections and hemolytic-uremic syndrome.
    Cimolai N
    CMAJ; 2001 May; 164(10):1405-6. PubMed ID: 11387906
    [No Abstract]   [Full Text] [Related]  

  • 2. Escherichia coli infections and hemolytic-uremic syndrome.
    Romney M
    CMAJ; 2001 May; 164(10):1406. PubMed ID: 11387907
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.
    O'Ryan M; Prado V
    N Engl J Med; 2000 Oct; 343(17):1271; author reply 1272-3. PubMed ID: 11183358
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.
    Aragón T; Fernyak S; Reiter R
    N Engl J Med; 2000 Oct; 343(17):1271-2; author reply 1272-3. PubMed ID: 11183357
    [No Abstract]   [Full Text] [Related]  

  • 5. E. coli, antibiotics and hemolytic-uremic syndrome in children.
    Farquhar D
    CMAJ; 2000 Aug; 163(4):438. PubMed ID: 10976267
    [No Abstract]   [Full Text] [Related]  

  • 6. E. coli, antibiotics, and the hemolytic-uremic syndrome.
    Zimmerhackl LB
    N Engl J Med; 2000 Jun; 342(26):1990-1. PubMed ID: 10874069
    [No Abstract]   [Full Text] [Related]  

  • 7. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota.
    Smith KE; Wilker PR; Reiter PL; Hedican EB; Bender JB; Hedberg CW
    Pediatr Infect Dis J; 2012 Jan; 31(1):37-41. PubMed ID: 21892124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimotility agents and E. coli infection.
    Tarr PI; Christie DL
    CMAJ; 1999 Apr; 160(7):984, 986. PubMed ID: 10207332
    [No Abstract]   [Full Text] [Related]  

  • 10. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.
    Wong CS; Jelacic S; Habeeb RL; Watkins SL; Tarr PI
    N Engl J Med; 2000 Jun; 342(26):1930-6. PubMed ID: 10874060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites.
    Nelson JM; Griffin PM; Jones TF; Smith KE; Scallan E
    Clin Infect Dis; 2011 May; 52(9):1130-2. PubMed ID: 21467017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can we predict the development of haemolytic uraemic syndrome in the early stage of Escherichia coli O157 infection?
    Joishy M; Jauhari P; Mathew AA; Rangarajan T
    Arch Dis Child; 2008 Feb; 93(2):180-1. PubMed ID: 18208996
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemolytic-uremic syndrome associated with Escherichia coli O157:H7.
    Weatherwax D; Lepow M
    Nephrol News Issues; 2000 Oct; 14(11):20-2. PubMed ID: 11933493
    [No Abstract]   [Full Text] [Related]  

  • 14. [Escherichia coli O157:H7 and hemolytic uremic syndrome in an HIV positive patient].
    García Lara FJ; Poves Martínez E; Cuadros González JA
    Rev Esp Enferm Dig; 2000 Dec; 92(12):820-1. PubMed ID: 11468790
    [No Abstract]   [Full Text] [Related]  

  • 15. Antimicrobial therapy in patients with Escherichia coli O157:H7 infection.
    Mølbak K; Mead PS; Griffin PM
    JAMA; 2002 Aug; 288(8):1014-6. PubMed ID: 12190374
    [No Abstract]   [Full Text] [Related]  

  • 16. Verocytotoxigenic Escherichia coli serologic responses in patients with hemolytic uremic syndrome.
    Goldwater PN; Bettelheim KA
    J Infect Dis; 2002 Aug; 186(4):582; author reply 582-3. PubMed ID: 12195391
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to Eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations.
    Saini A; Emke AR; Silva MC; Perlman SJ
    Clin Pediatr (Phila); 2015 Apr; 54(4):387-9. PubMed ID: 24817079
    [No Abstract]   [Full Text] [Related]  

  • 18. Child care-associated outbreak of Escherichia coli O157:H7 and hemolytic uremic syndrome.
    Raffaelli RM; Paladini M; Hanson H; Kornstein L; Agasan A; Slavinski S; Weiss D; Fennelly GJ; Flynn JT
    Pediatr Infect Dis J; 2007 Oct; 26(10):951-3. PubMed ID: 17901803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli.
    Mody RK; Luna-Gierke RE; Jones TF; Comstock N; Hurd S; Scheftel J; Lathrop S; Smith G; Palmer A; Strockbine N; Talkington D; Mahon BE; Hoekstra RM; Griffin PM
    Arch Pediatr Adolesc Med; 2012 Oct; 166(10):902-9. PubMed ID: 22869280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Enterohemorrhagic Escherichia coli--infection and a hemolytic uremic syndrome].
    Helminen M; Wisakanto KL; Raisio M; Baer M
    Duodecim; 1998; 114(3):229-32. PubMed ID: 10895492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.